Enjoy complimentary customisation on priority with our Enterprise License!
The uveitis drugs market share is expected to increase to USD 269.65 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%.
This uveitis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers uveitis drugs market segmentation by product (small molecules and biologics) and geography (North America, Europe, Asia, and Rest of World (ROW)). The uveitis drugs market report also offers information on several market vendors, including AbbVie Inc., Alimera Sciences Inc., Amgen Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Biogen Inc., Cadila Pharmaceuticals Ltd., EyePoint Pharmaceuticals Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sebela Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.
Download the Free Report Sample to Unlock the Uveitis Drugs Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The high prevalence of eye disorders and associated risk factors of uveitis is notably driving the uveitis drugs market growth, although factors such as adverse effects of corticosteroids may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the uveitis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Uveitis Drugs Market Driver
Key Uveitis Drugs Market Trend
Key Uveitis Drugs Market Challenge
This uveitis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global uveitis drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the uveitis drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the uveitis drugs market encompasses successful business strategies deployed by the key vendors. The uveitis drugs market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The uveitis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the uveitis drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
43% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for uveitis drugs in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.
The significant increase in the sales of approved drugs for the treatment of uveitis and the increasing prevalence of several associated risk factors for the condition will facilitate the uveitis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic had a negative impact on the growth of the regional uveitis drugs market in 2020. The pandemic led to a decline in the use of uveitis drugs in regional healthcare facilities due to the temporary suspension of ophthalmologic diagnostic services as well as procedures. However, the initiation of COVID-19 vaccination drives from December 2020 and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations in pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. Therefore, the regional uveitis drugs market is expected to witness growth during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The uveitis drugs market share growth by the small molecules segment will be significant during the forecast period. Small molecules are synthesized by chemical reactions between different organic and/or inorganic compounds. Corticosteroids such as prednisone (RAYOS), dexamethasone (DECADRON), and methylprednisolone (MEDROL) are largely used to treat uveitis. The increased use of corticosteroids for the treatment of uveitis, owing to the easy availability and low cost of corticosteroid generics, will drive the growth of the segment in focus in the coming years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the uveitis drugs market size and actionable market insights on post COVID-19 impact on each segment.
Uveitis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
Market growth 2022-2026 |
$ 269.65 million |
Market structure |
Fragmented |
YoY growth (%) |
5.3 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Alimera Sciences Inc., Amgen Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Biogen Inc., Cadila Pharmaceuticals Ltd., EyePoint Pharmaceuticals Inc., Hikma Pharmaceuticals Plc, Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sebela Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.